The COVID-19 virus may keep mutating, but new findings from Korean researchers at the Institute of Basic Science (IBS) offer a silver lining: human immunity is adapting, too.

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is awarding Syntiron US$1.7 million to develop a maternal vaccine that targets Escherichia coli and Klebsiella pneumoniae, two bacterial species that cause a large portion of neonatal sepsis infections.

Intravacc BV has been awarded funding for up to $633,000 from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) for the development of a preventive vaccine against Neisseria gonorrhoeae (NG), the bacterium that causes gonorrhea.

CC-chemokine receptor 3 (CCR3) is a member of the G protein-coupled, seven-transmembrane receptor family expressed on mouse eosinophils, basophils, mast cells and mononuclear phagocytes, among others, that plays a role in allergic diseases such as allergic rhinitis.

CD38 is the main NAD+-hydrolyzing enzyme, and it also catabolizes nicotinamide mononucleotide (NMN) and other extracellular NAD+ precursors prior to their intracellular transport for NAD+ biosynthesis.

Current risk genes for some diseases such as multiple sclerosis (MS) may have emerged in the past as protection against infection by different pathogens. A group of researchers led by scientists from the University of Copenhagen has analyzed the ancient DNA of European populations and has revealed how MS, Alzheimer’s disease (AD) and diabetes arose as populations migrated. This evolution would explain the modern genetic diversity and the incidences of these pathologies observed today in the old continent.